Hap Trading, LLC Biocryst Pharmaceuticals Inc Put Options Transaction History

Hap Trading, LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2022 Nov 14, 2022	SELL	$10.79 - $14.81 $11,868 - $16,291	-1,100 Reduced 7.14%	14,300 $58,000
Q2 2022 Aug 12, 2022	SELL	$7.89 - $17.88 $87,579 - $198,468	-11,100 Reduced 41.89%	15,400 $80,000
Q1 2022 May 12, 2022	SELL	$11.56 - $19.76 $1.41 Million - $2.41 Million	-121,900 Reduced 82.14%	26,500 $57,000
Q4 2021 Feb 14, 2022	BUY	$11.18 - $15.46 $195,650 - $270,550	17,500 Added 13.37%	148,400 $1.25 Million
Q3 2021 Nov 10, 2021	BUY	$14.21 - $17.65 $1 Million - $1.25 Million	70,600 Added 117.08%	130,900 $1.2 Million
Q2 2021 Aug 11, 2021	BUY	$9.5 - $17.24 $326,800 - $593,056	34,400 Added 132.82%	60,300 $123,000
Q1 2021 May 14, 2021	BUY	$7.37 - $13.61 $61,908 - $114,324	8,400 Added 48.0%	25,900 $84,000
Q4 2020 Feb 16, 2021	BUY	$3.37 - $8.61 $10,447 - $26,691	3,100 Added 21.53%	17,500 $48,000
Q2 2020 Aug 10, 2020	BUY	$1.9 - $5.61 $27,360 - $80,784	14,400 New	14,400 $11,000

278

172M

625K

739K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.45B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of Hap Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Hap Trading, LLC with notifications on news.